Blood Screening Market Trends and Overview

The screening market was estimated to be USD 2.6 billion in 2022 and is projected to reach USD 4.99 billion by 2030, with a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2023 to 2030.

This significant growth in the screening market can be attributed to various factors, including advancements in technology, increasing awareness about preventive healthcare, and the rising prevalence of chronic diseases. As a result, there is a growing demand for efficient and accurate screening methods to detect diseases at an early stage.

Furthermore, the adoption of digital screening solutions and the integration of artificial intelligence (AI) in screening processes have revolutionized the healthcare industry. These technological advancements have not only improved the accuracy and efficiency of screening tests but have also reduced the overall cost and time required for diagnosis.

Moreover, the COVID-19 pandemic has further emphasized the importance of screening in preventing the spread of infectious diseases. Governments and healthcare organizations worldwide have recognized the need for robust screening protocols to identify and isolate infected individuals promptly.

In conclusion, the screening market is poised for substantial growth in the coming years, driven by technological advancements, increasing healthcare awareness, and the need for early disease detection. As the demand for accurate and efficient screening methods continues to rise, the market is expected to witness significant investments and innovations, further propelling its growth.

Get Free Sample Report @


By Product & Service

  • Reagents & Kits
    • NAT Reagents & Kits
      • Enzymes & Polymerases
      • Standards & Controls
      • Probes & Primers
      • Buffers, Nucleotides, and Solutions
      • Labelling & Detection Reagents
    • ELISA Reagents & Kits
      • Immunosorbents
      • Controls
      • Conjugates
      • Substrates
      • Sample Diluents & Wash Solutions
    • Other Reagents & Kits
  • Instruments
    • Rental Purchase
    • Outright Purchase
  • Software & Services

By Technology

  • Nucleic Acid Test
    • Transcription-mediated Amplification
    • Real-time PCR
    • Chemiluminescent Immunoassays
    • Fluorescent Immunoassays
    • Colorimetric Immunoassays
  • Rapid Tests
  • Western Blot Assays
  • Next-generation Sequencing

By End User

  • Blood Banks
  • Hospitals

Some of the major key players are as follows: Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers, Ortho Clinical Diagnostics, Inc , BD, DiaSorin S.p.A., and others.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand — Head of Business Development & Strategy,

[email protected],

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND),